Godoy-Rivas Carlos, Elsadany Mohammed, Jaiswal Abhishek, Weissler-Snir Adaya, Arora Sabeena, Duvall W Lane
Division of Cardiology, Hartford Hospital, Hartford HealthCare Heart & Vascular Institute, Hartford, CT, USA.
Division of Cardiology, Hartford Hospital, Hartford HealthCare Heart & Vascular Institute, Hartford, CT, USA.
J Nucl Cardiol. 2024 Dec;42:102056. doi: 10.1016/j.nuclcard.2024.102056. Epub 2024 Oct 9.
Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.
The study incorporated a prospective, single-center study of ATTR patients being treated with tafamidis using Tc-99m-PYP SPECT/CT to quantify cardiac tracer uptake in the whole heart and left ventricle. Standardized uptake values (SUVs) were adjusted for blood pool activity. Comparison of baseline activity was made to values obtained approximately every 6 months during treatment.
Twenty-two patients (77.0±7.5 years old, 86.4% male) were on tafamidis for 15.3±4.0 months, with an average time between baseline and final follow-up study of 16.8±4.7 months. Thirteen patients (59.1%) had multiple follow-up amyloid studies. Statistically significant reductions in total SUVs, SUV volume, and percentage of injected dose were seen. Adjusted for the maximal aortic SUV, the total SUV in the left ventricle decreased by 36.9%, the SUV volume by 38.7%, and the percentage of injected dose decreased by 34.9% (all P values≤0.0001). Over the study duration, there was a decrease of 7.7%/month in the measured metrics.
The quantitative SUV measurements from Tc-99m-PYP SPECT/CT revealed an overall decrease in scintographic amyloid burden during the course of tafamidis therapy, but additional work is needed to determine the optimal metrics and improve the reproducibility of the quantification.
使用亲骨性示踪剂进行心脏成像以诊断转甲状腺素蛋白淀粉样变(ATTR)心脏淀粉样变性仅采用有限的定量分析,但单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)采集可提供示踪剂摄取定量的容积评估。他氟米特常用于治疗心脏淀粉样变性,但关于治疗期间成像结果变化的数据很少。本研究的目的是对锝-99m-焦磷酸盐(PYP)成像进行纵向评估,以确定他氟米特治疗是否会导致示踪剂摄取定量测量值发生任何变化。
该研究纳入了一项前瞻性、单中心研究,对接受他氟米特治疗的ATTR患者使用锝-99m-PYP SPECT/CT来量化全心脏和左心室的心脏示踪剂摄取。标准化摄取值(SUV)根据血池活性进行调整。将基线活性与治疗期间大约每6个月获得的值进行比较。
22例患者(77.0±7.5岁,86.4%为男性)接受他氟米特治疗15.3±4.0个月,基线与最终随访研究之间的平均时间为16.8±4.7个月。13例患者(59.1%)进行了多次随访淀粉样变研究。观察到总SUV、SUV容积和注射剂量百分比有统计学显著降低。以最大主动脉SUV进行校正后,左心室总SUV降低了36.9%,SUV容积降低了38.7%,注射剂量百分比降低了34.9%(所有P值≤0.0001)。在研究期间,测量指标每月下降7.7%。
来自锝-99m-PYP SPECT/CT的定量SUV测量显示,在他氟米特治疗过程中,闪烁显像淀粉样蛋白负荷总体下降,但需要进一步研究以确定最佳指标并提高定量的可重复性。